Briefs: Alembic Pharmaceuticals and Relonchem

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025

Alembic Pharmaceuticals Limited has received 11 US Food & Drug Administration (USFDA) product approvals (Final & Tentative) during the quarter ended 30th June, 2024.

Alembic has a cumulative total of 206 ANDA approvals (179 final approvals and 27 tentative approvals) from USFDA.

Relonchem receives UKMHRA marketing authorization for its products

Marksans Pharma Limited announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization from UKMHRA for the below mentioned products:

1. Rasagiline Relonchem 1 mg Tablets
2. Olmesartan 10 mg Film-coated Tablets
3. Olmesartan 20 mg Film-coated Tablets
4. Olmesartan 40 mg Film-coated Tablets